Announcement

Collapse
No announcement yet.

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment


    Engineering (Beijing). 2020 Feb 28. doi: 10.1016/j.eng.2020.02.006. [Epub ahead of print]
    Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.


    Chen J1, Hu C1, Chen L1, Tang L2, Zhu Y2, Xu X1, Chen L3, Gao H2, Lu X1, Yu L1, Dai X2, Xiang C1, Li L1,2.

    Author information




    Abstract

    H7N9 viruses quickly spread between mammalian hosts, and it carried out the risk of human-to-human transmission after outbreak in 2013. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was needed to treat H7N9 induced ARDS at the time. MSCs transplant into patients with H7N9 induced ARDS were conducted in a single center and open-label clinical trial. Based on the principle of voluntariness and informed consent, 44 patients with H7N9 induced ARDS were included as a control group while 17 patients with H7N9 induced ARDS were served as an experimental group with allogeneic menstrual blood-derived MSC. Notably, MSC transplantation significantly lower the mortality compared with in control group (17.6% died in MSC group vs 54.5% died in control group). Furthermore, MSC transplantation did not result in harmful effects in human body within the 5 year follow up period with 4 patients. Collectively, these results suggest that MSCs significantly improve survival rate of H7N9 induced ARDS and provide a theoretical basis for the treatment of H7N9 induced ARDS in both preclinical research and clinical studies. Because H7N9 and the corona virus disease 2019 (COVID-19) share similar complications (such as ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.
    ? 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.



    KEYWORDS:

    Acute respiratory distress syndrome; COVID-19; Epidemic Influenza A; H7N9; Mesenchymal stem cell; Stem cell therapeutics


    PMID:32292627PMCID:PMC7102606DOI:10.1016/j.eng.2020.02.006
    Free PMC Article

Working...
X